.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP54_ElbasvirAndGrazoprevir.ElbasvirAndGrazoprevir_1 .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP54_ElbasvirAndGrazoprevir.ElbasvirAndGrazoprevir_1| name: | ElbasvirAndGrazoprevir_1 | |
| ATC code: | J05AP54_1 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 1940 | L |
| clearance: | 36.6 | L/hr |
| other parameters in model implementation | ||
Elbasvir and grazoprevir is a fixed-dose combination of two direct-acting antiviral agents used for the treatment of chronic hepatitis C virus (HCV) infection. Elbasvir is an HCV NS5A inhibitor and grazoprevir is an HCV NS3/4A protease inhibitor. This combination is approved and in current clinical use for adults with genotype 1 or 4 HCV infection.
Pharmacokinetics in healthy adult subjects after a single tablet containing elbasvir 50 mg and grazoprevir 100 mg administered orally.
Marshall, WL, et al., & Yeh, WW (2018). Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. European journal of drug metabolism and pharmacokinetics 43(3) 321–329. DOI:10.1007/s13318-017-0451-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29247332